Clinical trialEPhase 1Not yet recruiting
Feasibility Study for Repurposing RET Inhibitors
Feasibility Study for Repurposing RET Inhibitors for Treating Cancer Cachexia
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 26 February 2026
- Expected end
- 23 February 2028
- Enrollment
- 7 participants
- Sites
- 1
- Primary outcomes
- Mean (± SD) changes in body weight after 12 weeks; Mean (± SD) percentage of doses of selpercatinib taken on time by patient
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 January 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This clinical trial aims to evaluate the feasibility of selpercatinib in addressing cachexia and anorexia among patients with non-small cell lung cancer (NSCLC), colorectal cancer, or pancreatic cancer who are eligible for platinum-based chemotherapy per standard of care. Participants will undergo blood draws at baseline and at 4, 8, and 12 weeks while on selpercatinib. At 16 weeks patients will return to the clinic for a weight assessment. Study evaluations will include the Functional Assessment of Anorexia Cachexia Therapy (FAACT), administered at screening, at 12 weeks post-discontinuation of the study drug, and again at the 16-week follow-up. In addition, several assessments of overall muscle strength and function will be conducted including a hallux strength assessment, sub-maximal leg press, sit-to-stand timing, grip strength, and ultrasound of the quadriceps. These will be conducted at baseline and again at 12 weeks end-of-treatment.